| 1.53 -0.17 (-10%) | 04-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 3  |
1-year : | 3.78 |
| Resists | First : | 2.57 |
Second : | 3.24 |
| Pivot price | 2.25 |
|||
| Supports | First : | 1.5 |
Second : | 1.24 |
| MAs | MA(5) : | 1.87 |
MA(20) : | 2.4 |
| MA(100) : | 3.17 |
MA(250) : | 2.5  |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 6.4 |
D(3) : | 8.2 |
| RSI | RSI(14): 24.9 |
|||
| 52-week | High : | 5.25 | Low : | 0.39 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ RENB ] has closed below the lower bollinger band by 2.5%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ RENB ] is to continue within current trading range. Bollinger Bands are 6.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.11 - 2.13 | 2.13 - 2.15 |
| Low: | 1.47 - 1.49 | 1.49 - 1.5 |
| Close: | 1.51 - 1.54 | 1.54 - 1.56 |
Renovaro Biosciences Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Enochian Biosciences, Inc. and changed its name to Renovaro Biosciences Inc. in August 2023. Renovaro Biosciences Inc. is headquartered in Los Angeles, California.
Wed, 13 Mar 2024
Renovaro Biosciences Appoints Simon Tarsh as Interim CFO - TipRanks.com - TipRanks
Mon, 11 Mar 2024
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Renovaro Biosciences Inc ... - PR Newswire
Fri, 16 Feb 2024
Renovaro Biosciences Secures $3 Million in Growth Financing - TipRanks.com - TipRanks
Wed, 14 Feb 2024
Renovaro Inc. Expands with Strategic Acquisition and Equity Changes - TipRanks.com - TipRanks
Wed, 14 Feb 2024
Renovaro defends its RenovaroCube tech amid short-seller attack - Investing.com
Wed, 14 Feb 2024
Hit With Short Seller Report, Renovaro Biosciences Comments On Hindenburg's Opinion Piece - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 144 (M) |
| Shares Float | 102 (M) |
| Held by Insiders | 26.2 (%) |
| Held by Institutions | 1.8 (%) |
| Shares Short | 2,320 (K) |
| Shares Short P.Month | 826 (K) |
| EPS | -0.7 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.64 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -19.2 % |
| Return on Equity (ttm) | -74.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.15 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -11 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -2.19 |
| PEG Ratio | 0 |
| Price to Book value | 2.35 |
| Price to Sales | 0 |
| Price to Cash Flow | -19.14 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|